Search research articles
Contact Us
Filters
Showing results (161-170 of 169) with videos related to
Page
of 17
Sort By:
You have reached the last page of results.
This site can display upto 169 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 23, 2024
A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial
G N Hortobagyi, A Lacko, J Sohn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 8, 2021
Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy<sup>⋆</sup>
C Denkert, M Untch, S Benz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2018
Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto
S Loibl, K E Weber, K M Timms, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 1, 2021
Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE
E P Mamounas, M Untch, M S Mano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 26, 2008
Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial
M Untch, R D Gelber, C Jackisch, et al.
ESMO Open
|
October 17, 2024
Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)]
E de Azambuja, M Piccart-Gebhart, S Fielding, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 16, 2015
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)
S Gourgou-Bourgade, D Cameron, P Poortmans, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 1, 2015
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†
S Gourgou-Bourgade, D Cameron, P Poortmans, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 17, 2014
Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†
G von Minckwitz, S Loibl, M Untch, et al.
Page
of 17
Search research articles
Search
Showing results (161-170 of 169) with videos related to
Sort By:
Page
of 17
You have reached the last page of results.
This site can display upto 169 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 23, 2024
A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial
G N Hortobagyi, A Lacko, J Sohn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 8, 2021
Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy<sup>⋆</sup>
C Denkert, M Untch, S Benz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2018
Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto
S Loibl, K E Weber, K M Timms, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 1, 2021
Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE
E P Mamounas, M Untch, M S Mano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 26, 2008
Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial
M Untch, R D Gelber, C Jackisch, et al.
ESMO Open
|
October 17, 2024
Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)]
E de Azambuja, M Piccart-Gebhart, S Fielding, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 16, 2015
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)
S Gourgou-Bourgade, D Cameron, P Poortmans, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 1, 2015
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†
S Gourgou-Bourgade, D Cameron, P Poortmans, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 17, 2014
Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†
G von Minckwitz, S Loibl, M Untch, et al.
Page
of 17